J&J ups the ante in battle for Remicade and Simponi

Date May 28, 2009

Johnson & Johnson has fired its first shot across the bows of Schering-Plough in the war for control of Remicade and Simponi. The group has filed for arbitration to end its partnership with Schering, claiming that Schering's reverse merger with Merck & Co constitutes a change of control.

This decision by J&J is understandable, and as previously pointed out by EP Vantage (Nothing ventured, nothing gained for J&J, May 21, 2009) out of the two groups J&J has the least to lose. If it does not succeed in getting full control of Remicade and Simponi, the only thing it will have to do is pay its lawyers and continue to enjoy the already lucrative existing deal terms.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd